Safety Trial of Naproxen Sodium/ Diphenhydramine (MUST)
This study has been completed.
Sponsor:
Bayer
Information provided by:
Bayer
ClinicalTrials.gov Identifier:
NCT01365052
First received: May 17, 2011
Last updated: August 9, 2012
Last verified: August 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this trial is to see how safe the combination of naproxen sodium 440 mg and diphenhydramine hydrochloride (DPH) 50 mg (the investigational product) is compared to placebo (capsules containing no drug) when taken for 10 days.
| Condition | Intervention | Phase |
|---|---|---|
|
Pain |
Drug: BAY98-7111 Drug: Placebo |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) |
| Official Title: | A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Safety and Tolerability Trial of Naproxen Sodium/ Diphenhydramine Combination in an OTC Population |
Resource links provided by NLM:
Drug Information available for:
Promethazine hydrochloride
Diphenhydramine
Promethazine
Diphenhydramine hydrochloride
Naproxen
Naproxen sodium
Diphenhydramine citrate
U.S. FDA Resources
Further study details as provided by Bayer:
Primary Outcome Measures:
- Incidence of adverse events by body system and preferred term [ Time Frame: After 10 days ] [ Designated as safety issue: Yes ]
- The proportion of subjects who discontinued due to an adverse event for those subjects who are randomized and take at least one dose of investigational product [ Time Frame: After 10 days ] [ Designated as safety issue: Yes ]
| Enrollment: | 326 |
| Study Start Date: | May 2011 |
| Study Completion Date: | July 2011 |
| Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Arm 1 |
Drug: BAY98-7111
440 mg naproxen sodium/ 50 mg diphenhydramine; oral capsule qd 30 minutes prior to bedtime
|
| Placebo Comparator: Arm 2 |
Drug: Placebo
Placebo oral capsule qd 30 minutes prior to bedtime
|
Eligibility| Ages Eligible for Study: | 12 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Healthy, ambulatory, male and female volunteers ages 12 and older
- History of experiencing occasional sleeplessness accompanied by aches and pains at least two times, but not continually for more than 14 days per month, in at least 2 of the past 3 months
- Female subjects of childbearing potential must be using a medically acceptable form of birth control, e.g., oral or patch contraceptives, intrauterine device, Depo-Provera®, for at least 1 month prior to screening (3 months on oral contraceptives), or double-barrier and have a negative pregnancy test at Screening. Female subjects of nonchildbearing potential must be amenorrheic for at least 2 years or have had a hysterectomy and/or bilateral oophorectomy
- Be willing and able to participate in all scheduled visits, treatment plan, tests and other trial procedures according to the protocol
- Provide a personally signed and dated informed consent indicating that the subject has been informed of all pertinent aspects of the trial, (subjects <18 years of age must sign a written assent and have parental or guardian consent).
Exclusion Criteria:
- History of hypersensitivity to naproxen sodium, acetaminophen, or any NSAIDs, diphenhydramine or any other antihistamines, and similar pharmacological agents or components of the product
- Evidence or history of clinically significant (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or malignancies with the last 5 years
- A history of a chronic or severe sleep problem which does not respond to OTC medication and/or requires a prescription hypnotic or sedative
- Currently experiencing chronic pain or on chronic NSAID therapy (defined as taking a daily [5 to 7 days per week] regimen of prescription or OTC NSAIDs)
- Current or past history of gastrointestinal ulcers or bleeding or other bleeding disorders
- Use of any OTC or prescription medications with which the administration of naproxen, acetaminophen, or any NSAIDs, diphenhydramine or any other antihistamines or sedatives, is contraindicated
- Chronic use of other products containing diphenhydramine, including topical products
- Use of steroids or blood thinning (anticoagulant) drugs (aspirin 81 mg is permitted if the dose has been taken for at least one month prior to screening)
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01365052
Locations
| United States, Arizona | |
| Chandler, Arizona, United States, 85224 | |
| Mesa, Arizona, United States, 85203 | |
| Peoria, Arizona, United States, 85381 | |
| United States, California | |
| Anaheim, California, United States, 92801 | |
| Rancho Cucamonga, California, United States, 91730 | |
| Sacramento, California, United States, 95816 | |
| United States, Colorado | |
| Colorado Springs, Colorado, United States, 80922 | |
| United States, Florida | |
| Kissimmee, Florida, United States, 34741 | |
| Pembroke Pines, Florida, United States, 33028 | |
| South Miami, Florida, United States, 33143 | |
| United States, Georgia | |
| Stockbridge, Georgia, United States, 30281 | |
| United States, Louisiana | |
| Metairie, Louisiana, United States, 70006 | |
| United States, Maryland | |
| Elkridge, Maryland, United States, 21075 | |
| United States, Rhode Island | |
| Warwick, Rhode Island, United States, 02886 | |
| United States, South Carolina | |
| Mt. Pleasant, South Carolina, United States, 29464 | |
| United States, Texas | |
| Fort Worth, Texas, United States, 76135 | |
| San Angelo, Texas, United States, 76904 | |
| San Antonio, Texas, United States, 78231 | |
| United States, Utah | |
| Salt Lake City, Utah, United States, 84106 | |
Sponsors and Collaborators
Bayer
Investigators
| Study Director: | Bayer Study Director | Bayer |
More Information
Additional Information:
No publications provided
| Responsible Party: | Head Clinical and Medical Affairs, Bayer Consumer Care Inc. |
| ClinicalTrials.gov Identifier: | NCT01365052 History of Changes |
| Other Study ID Numbers: | 15560 |
| Study First Received: | May 17, 2011 |
| Last Updated: | August 9, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Bayer:
|
Maximum Use Safety Trial |
Additional relevant MeSH terms:
|
Naproxen Diphenhydramine Promethazine Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents Gout Suppressants Cyclooxygenase Inhibitors |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Central Nervous System Agents Antiemetics Autonomic Agents Gastrointestinal Agents Histamine H1 Antagonists Histamine Antagonists Histamine Agents Neurotransmitter Agents Hypnotics and Sedatives Central Nervous System Depressants Anti-Allergic Agents Anesthetics, Local Anesthetics |
ClinicalTrials.gov processed this record on May 22, 2013